How can we assess quality of life in AML patients?
Exploring combinatorial approaches in acute myeloid leukemia (AML) treatment
Francesco Lo Coco
New drug targets for AML
Results of the Phase III DASISION trial and the future of CML treatment
FLT3 inhibitors – an ideal strategy for treating FLT3-mutated AML